These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26849511)

  • 1. Fresh from the biotech pipeline--2015.
    Morrison C
    Nat Biotechnol; 2016 Feb; 34(2):129-32. PubMed ID: 26849511
    [No Abstract]   [Full Text] [Related]  

  • 2. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent developments help the defense of drug companies in 10b-5 cases.
    Salpeter AN; Hutchins H
    Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotech battle royale. Two firms fight over billion-dollar drug.
    Sherrid P
    US News World Rep; 2000 Mar; 128(11):52. PubMed ID: 10848209
    [No Abstract]   [Full Text] [Related]  

  • 5. Out-licensing role reversal.
    Morrison C
    Nat Rev Drug Discov; 2017 Mar; 16(3):151-152. PubMed ID: 28248940
    [No Abstract]   [Full Text] [Related]  

  • 6. Biotech industry struggles with generics approval.
    Knight J
    Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
    [No Abstract]   [Full Text] [Related]  

  • 7. Spreading biotech dollars around Washington.
    Senior M
    Nat Biotechnol; 2013 Aug; 31(8):673-5. PubMed ID: 23929333
    [No Abstract]   [Full Text] [Related]  

  • 8. Biotech boot camp.
    Ledford H
    Nature; 2015 Mar; 519(7544):402-5. PubMed ID: 25810186
    [No Abstract]   [Full Text] [Related]  

  • 9. Barnyard biotech--lame duck or golden goose?
    Powell K
    Nat Biotechnol; 2003 Sep; 21(9):965-7. PubMed ID: 12949546
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotech entrepreneurs swoon over proposed fundraising changes.
    Venkataramanan M
    Nat Med; 2012 Jan; 18(1):3. PubMed ID: 22227645
    [No Abstract]   [Full Text] [Related]  

  • 11. How FDA approves biotechnology drugs.
    Manuel SM; Piascik P
    Am Pharm; 1995 May; NS35(5):14-5. PubMed ID: 7611131
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulatory evaluation of biotechnology drugs: current trends in the United States.
    Sobel S
    Bioprocess Technol; 1991; 13():499-511. PubMed ID: 1367148
    [No Abstract]   [Full Text] [Related]  

  • 13. BIO and biogenerics.
    Feldbaum CB
    Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
    [No Abstract]   [Full Text] [Related]  

  • 14. Drugs with breakthrough status charm investors.
    Senior M
    Nat Biotechnol; 2013 Nov; 31(11):945-7. PubMed ID: 24213748
    [No Abstract]   [Full Text] [Related]  

  • 15. Biogenerics standoff.
    Herrera S
    Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
    [No Abstract]   [Full Text] [Related]  

  • 16. An industry imperiled by regulatory bottlenecks.
    Naughton G
    Nat Biotechnol; 2001 Aug; 19(8):709-10. PubMed ID: 11479550
    [No Abstract]   [Full Text] [Related]  

  • 17. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 18. Overdue process.
    Nat Biotechnol; 2004 Nov; 22(11):1329. PubMed ID: 15529137
    [No Abstract]   [Full Text] [Related]  

  • 19. Training needs in regulatory science for the biopharmaceutical industry.
    Gundersen LE
    Nat Biotechnol; 2001 Dec; 19(12):1187-8. PubMed ID: 11731794
    [No Abstract]   [Full Text] [Related]  

  • 20. Fresh from the biotech pipeline--2013.
    Kling J
    Nat Biotechnol; 2014 Feb; 32(2):121-4. PubMed ID: 24509747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.